Rumpshaker Behaves like Juvenile-Lethal Plp Mutations When Combined with Shiverer in Double Mutant MiceBillings-Gagliardi S. · Nunnari J.J. · Wolf M.K.
Department of Cell Biology, University of Massachusetts Medical School, Worcester, Mass., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The phenotypes of double mutant mice whose genomes are homozygous for an Mbp (myelin basic protein) mutation and hemizygous for a juvenile-lethal Plp (proteolipid protein) mutation were compared in earlier studies. The results suggested that the shiverer Mpb mutation might have some unexplained ability to partially rescue oligodendrocytes (OLs) from the ‘death sentence’ that is imposed by the Plp mutations. Conversely, they also indicated that the juvenile-lethal Plp mutations may normalize shiverer OL morphology by reducing the numbers of microprocesses. The Plp mutation rumpshaker produces a mild hypomyelination without reduction in OL numbers and a normal lifespan. This report describes double mutant mice combining two Mbp mutations with rumpshaker, utilizing a common B6C3F1 hybrid-based genetic background. Initial studies on B6C3F1 rumpshaker optic nerve and spinal cord white matter showed unanticipated signs of OL death, with morphologic criteria suggestive of an apoptotic mechanism. In shiverer*rumpshaker double mutant mice, this small class of dying cells could not be identified. White matter morphology was similar to that of mice expressing only the shiverer mutation, except that OL microprocesses were far less abundant. This evidence suggests that, despite their distinctive phenotypic differences, rumpshaker may share more characteristics with the juvenile-lethal Plp mutations than has previously been recognized.
© 2001 S. Karger AG, Basel
- Macklin WB, Gardinier MV, King KD, Kampf K: An AG → GG transition at a splice site in the myelin proteolipid gene in jimpy mice results in the removal of an exon. FEBS Lett 1987;223:417–421.
- Nave K-A, Bloom FE, Milner RJ: A single nucleotide difference in the gene for myelin proteolipid protein defines the jimpy mutation in the mouse. J Neurochem 1987;49:1873–1877.
- Gencic S, Hudson LD: Conservative amino acid substitution in the myelin proteolipid protein of jimpymsd mice. J Neurosci 1990;10:117–124.
- Meier C, Herschkowitz N, Bischoff A: Morphological and biochemical observations in the Jimpy spinal cord. Acta Neuropathol (Berl) 1974;27:349–362.
- Billings-Gagliardi S, Adcock LH, Wolf MK: Hypomyelinated mutant mice: Description of jpmsd and comparison with jp and qk on their present genetic backgrounds. Brain Res 1980;194:325–338.
- Duncan ID, Hammang JP, Goda S, Quarles RH: Myelination in the jimpy mouse in the absence of proteolipid protein. Glia 1989;2:148–154.
- Knapp P, Skoff R, Redstone D: Oligodendroglial cell death in jimpy mice: An explanation for the myelin deficit. J Neurosci 1986;6:2813–2822.
- Skoff RP: Programmed cell death in the dysmyelinating mutants. Brain Pathol 1995;5:283–288.
- Gow A, Southwood CM, Lazzarini RA: Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J Cell Biol 1998;140:925–934.
- Roussel G, Neskovic NM, Trifilieff E, Artault J-C, Nussbaum J-L: Arrest of proteolipid transport through the Golgi apparatus in jimpy brain. J Neurocytol 1987;16:195–204.
Gow A, Friedrich VL, Lazzarini RA: Many naturally occurring mutations of myelin proteolipid protein impair its intracellular transport. J Neurosci Res 1994;37:547–583.
- Gow A, Lazzarini RA: A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nat Genet 1996;13:422–428.
- Jung M, Sommer I, Schachner M, Nave K-A: Monoclonal antibody O10 defines a conformationally sensitive cell-surface epitope of proteolipid protein (PLP): Evidence that PLP misfolding underlies dysmyelination in mutant mice. J Neurosci 1996;16:7920–7929.
- Thomson CE, Montague P, Jung M, Nave K-A, Griffiths IR: Phenotypic severity of murine Plp mutants reflects in vivo and in vitro variations in transport of PLP isoproteins. Glia 1997;20:322–332.
- Roach A, Takahashi N, Pravtcheve D, Ruddle F, Hood L: Chromosomal mapping of mouse myelin basic protein gene and structure and transcription of the partially deleted gene in shiverer mutant mice. Cell 1985;42:149–155.
- Popko B, Puckett C, Hood L: A novel mutation in myelin-deficient mice results in unstable myelin basic protein gene transcripts. Neuron 1988;1:221–225.
- Billings-Gagliardi S, Wolf MK, Kirschner DA, Kerner A-L: Shiverer*jimpy double mutant mice. II. Morphological evidence supports reciprocal intergenic suppression. Brain Res 1986;374:54–62.
- Sinclair A, Raz Y, Kirschner DA, Villa-Komaroff L, Wolf MK, Billings-Gagliardi S: Shiverer*jimpy double mutant mice V: Correlation of genotype and myelin proteins. Dev Neurosci 1991;13:138–142.
- Billings-Gagliardi S, Wolf MK: Shiverer*jimpy double mutant mice IV. Five combinations of allelic mutations produce three morphological phenotypes. Brain Res 1988;455:271–282.
- Schneider A, Montague P, Griffiths I, Fanarraga M, Kennedy P, Brophy P, Nave K-A: Uncoupling of hypomyelination and glial cell death by a mutation in the proteolipid protein gene. Nature 1992;358:758–761.
- Fanarraga ML, Sommer IU, Griffiths IR, Montague P, Groome NP, Nave K-A, Schneider A, Brophy PJ, Kennedy PGE: Oligodendrocyte development and differentiation in the rumpshaker mutation. Glia 1993;9:146–156.
- Fanarraga ML, Griffiths IR, McCulloch MC, Barrie JA, Kennedy PGE, Brophy PJ: Rumpshaker: An X-linked mutation causing hypomyelination: Developmental differences in myelination and glial cells between the optic nerve and spinal cord. Glia 1992;5:161–170.
- Griffiths IR, Scott I, McCulloch MC, Barrie JA, McPhilemy K, Cattanach BM: Rumpshaker mouse: A new X-linked mutation affecting myelination: Evidence for a defect in PLP expression. J Neurocytol 1990;19:273–283.
- Klugmann M, Schwab MH, Pühlhofer A, Schneider A, Zimmermann F, Griffiths IR, Nave K-A: Assembly of CNS myelin in the absence of proteolipid protein. Neuron 1997;18:59–70.
- Boison D, Stoffel W: Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc Natl Acad Sci USA 1994;91:11709–11713.
- Stoffel W, Boison D, Büssow H: Function analysis in vivo of the double mutant mouse deficient in both proteolipid protein (PLP) and the myelin basic protein (MBP) in the central nervous system. Cell Tissue Res 1997;289:195–206.
- Kagawa T, Ikenaka K, Inoue Y, Kuriyama S, Tsujii T, Nakao J, Nakajima K, Aruga J, Okano H, Mikoshiba K: Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron 1994;13:427–442.
- Nadon NL, Arnheiter H, Hudson LD: A combination of PLP and DM20 transgenes promotes partial myelination in the jimpy mouse. J Neurochem 1994;63:822–833.
- Readhead C, Schneider A, Griffiths I, Nave K-A: Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron 1994;12:583–595.
- Schneider A, Griffiths I, Readhead C, Nave K-A: Dominant-negative action of the jimpy mutation in mice complemented with an autosomal transgene for myelin proteolipid protein. Proc Natl Acad Sci USA 1995;92:4447–4451.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.